SuperworthBio-Rad Laboratories EPS BIO
Diluted earnings per share by quarter and over the last twelve months, from 2009.
- Last 12 months, to Jun 30, 2026
- $8.25
- Latest quarter, Q2 FY26
- $13.85
- +19% on a year earlier
- Fiscal year 2025
- $27.91
Bio-Rad Laboratories' earnings per share was $8.25 over the twelve months to Jun 30, 2026, down 30% on a year earlier.
In its latest quarter, Q2 FY26, it was $13.85, up 19% on the same quarter a year before.
Over the five fiscal years to FY2025 it shrank 26% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $27.91 | n/a |
| FY2024 | −$65.03 | n/a |
| FY2023 | −$21.49 | n/a |
| FY2022 | −$121.25 | −186% |
| FY2021 | $140.36 | +11% |
| FY2020 | $126.32 | +117% |
| FY2019 | $58.23 | +393% |
| FY2018 | $11.80 | +191% |
| FY2017 | $4.06 | +361% |
| FY2016 | $0.88 | −77% |
| FY2015 | $3.85 | +26% |
| FY2014 | $3.05 | +13% |
| FY2013 | $2.69 | −53% |
| FY2012 | $5.73 | −8% |
| FY2011 | $6.26 | −5% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $13.85 | +19% | $8.25 | |
| Q1 FY26 | −$19.55 | −954% | $6.07 | |
| Q4 FY25 | $26.65 | n/a | $27.91 | |
| Q3 FY25 | −$12.70 | −154% | −$24.30 | |
| Q2 FY25 | $11.67 | n/a | $11.74 | |
| Q1 FY25 | $2.29 | −83% | −$76.19 | |
| Q4 FY24 | −$25.56 | −311% | −$65.03 | |
| Q3 FY24 | $23.34 | +541% | −$27.33 | |
| Q2 FY24 | −$76.26 | n/a | −$47.03 | |
| Q1 FY24 | $13.45 | +480% | −$10.36 | |
| Q4 FY23 | $12.14 | −56% | −$21.49 | |
| Q3 FY23 | $3.64 | n/a | −$5.85 |
Against its peers
Companies in Medical - Diagnostics & Research nearest Bio-Rad Laboratories' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| BIOBio-Rad Laboratories | $8.25 | −30% a year |
| CAICaris Life Sciences | $0.37 | |
| LNTHLantheus | $4.13 | +10% a year |
| RVTYRevvity | $2.10 | −11% a year |
| MEDPMedpace | $17.05 | +27% a year |
| BLLNBillionToOne | $0.65 | |
| VCYTVeracyte | $1.40 | +324% a year |
| LHLabcorp | $12.09 | +33% a year |
| DGXQuest Diagnostics | $9.41 | +18% a year |
| CDNACareDx | $2.07 | +116% a year |
| MTDMettler-Toledo International | $44.42 | +12% a year |
| Peer median | $3.12 |
Where Bio-Rad Laboratories ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Bio-Rad Laboratories
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.